5th Circ. Mulls New Trial Bid In Sanofi Chemo Bellwether
Law360 (July 21, 2021, 4:36 PM EDT) -- A Fifth Circuit panel questioned during oral arguments on Wednesday whether a new trial should be granted to the plaintiff in the first bellwether trial against Sanofi over permanent hair loss allegedly linked to its chemotherapy drug Taxotere.
Plaintiff Barbara Earnest told the panel that Sanofi US Services Inc.'s sole expert witness, Dr. John Glaspy, was wrongly allowed to tell the jury it should trust a reanalysis of a pivotal drug trial conducted by a former employee, Dr. Michael Kopreski, who testified for the company. Glaspy never independently verified that reanalysis, which Earnest says jurors were told shows only rare instances...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!